Recent advances in sensitive surface-enhanced Raman scattering-based lateral flow assay platforms for point-of-care diagnostics of infectious diseases

Kihyun Kim; Leila Kashefi-Kheyrabadi; Younju Joung; Kyeongnyeon Kim; Hajun Dang; Sachin Ganpat Chavan; Min-Ho Lee; Jaebum Choo

doi:10.1016/j.snb.2020.129214

Recent advances in sensitive surface-enhanced Raman scattering-based lateral flow assay platforms for point-of-care diagnostics of infectious diseases

Sens Actuators B Chem. 2021 Feb 15:329:129214. doi: 10.1016/j.snb.2020.129214. Epub 2020 Nov 19.

Authors

Kihyun Kim¹, Leila Kashefi-Kheyrabadi², Younju Joung¹, Kyeongnyeon Kim¹, Hajun Dang¹, Sachin Ganpat Chavan², Min-Ho Lee², Jaebum Choo¹

Affiliations

¹ Department of Chemistry, Chung-Ang University, Seoul, 06974, South Korea.
² School of Integrative Engineering, Chung-Ang University, Seoul, 06974, South Korea.

Abstract

This review reports the recent advances in surface-enhanced Raman scattering (SERS)-based lateral flow assay (LFA) platforms for the diagnosis of infectious diseases. As observed through the recent infection outbreaks of COVID-19 worldwide, a timely diagnosis of the disease is critical for preventing the spread of a disease and to ensure epidemic preparedness. In this regard, an innovative point-of-care diagnostic method is essential. Recently, SERS-based assay platforms have received increasing attention in medical communities owing to their high sensitivity and multiplex detection capability. In contrast, LFAs provide a user-friendly and easily accessible sensing platform. Thus, the combination of LFAs with a SERS detection system provides a new diagnostic modality for accurate and rapid diagnoses of infectious diseases. In this context, we briefly discuss the recent application of LFA platforms for the POC diagnosis of SARS-CoV-2. Thereafter, we focus on the recent advances in SERS-based LFA platforms for the early diagnosis of infectious diseases and their applicability for the rapid diagnosis of SARS-CoV-2. Finally, the key issues that need to be addressed to accelerate the clinical translation of SERS-based LFA platforms from the research laboratory to the bedside are discussed.

Keywords: AuNPs, gold nanoparticles; BA, bacillary angiomatosis; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeat; HIV, human immunodeficiency virus; IFA, indirect immunofluorescence assay; IgG, immunoglobulin G; IgM, immunoglobulin M; In vitro diagnostics (IVD); Infectious disease; KSHV, Kaposi’s sarcoma herpes virus; LFA, lateral flow assay; Lateral flow assay (LFA); NC, nitrocellulose; NS1, nonstructural protein 1; POC, point-of-care; PRV, pseudorabies virus; Point-of-care (POC); RT-PCR, real-time polymerase chain reaction; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; SEB, staphylococcal enterotoxin; SERS, surface-enhanced Raman scattering; Si-AuNPs, silica-encapsulated AuNPs; Surface-enhanced Raman scattering (SERS); crRNAs, CRISPR RNAs.